Recent Securities Litigations

Intellipharmaceutics International Inc. (NASDAQ: IPCI)

Company Name:Intellipharmaceutics International Inc.
Stock Symbol:NASDAQ: IPCI
Class Period Start:05/21/2015
Class Period End (inclusive):07/26/2017

According to the Complaint, Intellipharmaceutics is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's main product candidate is Rexista, an abuse-deterrent oxycodone hydrochloride extended release tablets. Rexista is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

The Complaint alleges the Company made materially false and/or misleading statements regarding its New Drug Application ("NDA") with the U.S. Food and Drug Administration ("FDA") seeking authorization to market its Rexista product.